Metabolomic biomarkers in women with polycystic ovary syndrome: A pilot study

Molecular Human Reproduction

Volumn 18, Issue 11, 2012, Pages 546-553

  Atiomo, W ^a   Daykin, C A ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Metabolomics; Metabonomics; Ovary; PCOS; Polycystic

Indexed keywords

ACETONE; ARGININE; CITRIC ACID; CITRULLINE; GLUTAMIC ACID; HISTIDINE; LYSINE; ORNITHINE; PROLINE;

ADULT; AMINO ACID BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISCRIMINANT ANALYSIS; FEASIBILITY STUDY; FEMALE; HUMAN; METABOLOMICS; OVARY POLYCYSTIC DISEASE; PARTIAL LEAST SQUARES REGRESSION; PILOT STUDY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; UNIVARIATE ANALYSIS; VEIN PUNCTURE;

ADULT; AMINO ACIDS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CITRIC ACID; FEMALE; HUMANS; INSULIN; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; PRINCIPAL COMPONENT ANALYSIS;

EID: 84868036417     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gas029     Document Type: Article

References (31)

1. 1H NMR spectroscopy of human blood plasma. Prog Nucl Magn Reson Spectrosc 1995;27:475-554.
2. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935.
3. Atiomo W, Khalid S, Parameshweran S, Houda M, Layfield R. Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: a systematic review. BJOG 2009;116:137-143.
4. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
5. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
6. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-35.
7. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011;43:55-59.
8. Choi BC, Kim YS, Kim MS, Chung MK, Choi CH, Baek KH. Identification of over expressed proteins by proteomic analysis using human follicular fluids derived from polycystic ovary syndrome (PCOS) patients. Fertil Steril 2007;88:S180.
9. Córton M, Botella-Carretero JI, López JA, Camafeita E, San Millán JL, Escobar-Morreale HF, Peral B. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Hum Reprod 2008;23:651-661.
10. Daykin CA, Wulfert F, Bro R. Data handling for interactive metabolomics: tools for studying the dynamics of metabolome-macromolecule interactions. Metabolomics 2012;8:52-63.
11. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One 2010;5:e15234.
12. Foster Daniel W. Studies in the ketosis of fasting. J Clin Invest 1967; 46:1283-1296.
13. Glueck JC, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with healthy female population. Metab Clin Exp 2009;58:714-721.
14. Goodarzi MO. Looking for polycystic ovary syndrome genes: rational and best strategy. Sem Rep Med 2008;26:5-13.
15. Hughes C, Elgasim M, Layfield R, Atiomo W. Genomic and post-genomic approaches to polycystic ovary syndrome-progress so far: mini review. Hum Reprod 2006;21:2766-2775.
16. Insenser M, Marti{dotless}́nez-Garci{dotless}́a MA, Montes R, San-Millan JR, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J Clin Endocrinol Metab 2010; 95:3863-3870.
17. Kafkewitz D, Bendich A. Enzyme-induced asparagine and glutamine depletion and immune system function. Am J Clin Nutr 1983;37:1025-1030.
18. Krentz AJ, von Muhlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007;14:284-292.
19. Liye Sun, Weihong Hu, Qiao Liu, Qinfang Hao, Bo Sun, Qi Zhang, Sha Mao, Jie Qiao, Xianzhong Yan. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res 2012;11:2937-2946.
20. Luque-Ramirez M, San Millan JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clin Chim Acta 2006;366:14-26.
21. Ma X, Fan L, Meng Y, Hou Z, Mao YD, Wang W, Ding W, Liu JY. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod 2007;13:527-535.
22. Matharoo-Ball B, Hughes C, Lancashire L, Tooth D, Ball G, Creaser C, Elgasim M, Rees R, Layfield R, Atiomo W. Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. J Proteome Res 2007;6:3321-3328.
23. Mihalik SJ, Michaliszyn SF, de las Heras J, Bacha F, Lee S, Chace DH, DeJesus VR, Vockley J, Arslanian SA. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care 2012;35:605-611.
24. Nicholson JK, Foxall PJD, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995;67:793-811.
25. O'Dwyer ST, Smith RJ, Hwang TL, Wilmore DW. Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. JPEN J Parenter Enteral Nutr 1989;13:579-585.
26. Reo NV. NMR-based metabolomics. Drug Chem Toxicol 2002;25:375-382.
27. Setji TL, Brown AJ. Polycystic ovary syndrome: diagnosis and treatment. Am J Med 2007;120:128-132.
28. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93:1276-1284.
29. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic syndrome (PCOS). Hum Reprod 2004;19:41-47.
30. Urbanek M, Legro RS, Driscoll DA. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad USA 1999;96:8573-8578.
31. Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbanek M, McAllister JM, Mosselman S, Strauss JF III. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 2003; 278:26380-26390.